Evidence map›Paper›PMID 36032172›Full record

ArticleFrontiers in immunology2022

Complement lectin pathway components MBL and MASP-1 promote haemostasis upon vessel injury in a microvascular bleeding model.

Murielle Golomingi, Jessie Kohler, Lorenz Jenny, Elaissa T Hardy, József Dobó, Péter Gál, Gábor Pál, Bence Kiss, Wilbur A Lam, Verena Schroeder

Open access · goldAbstract read
In one paragraph

Article in Frontiers in immunology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
0.9field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 12 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
  6. Review
  7. Article
  8. Integration of immune cells in organs-on-chips: a tutorial.Frontiers in bioengineering and biotechnology · 2023
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 5 institutions in 3 countries.

Murielle GolomingiExperimental Haemostasis Group, Department for BioMedical Research, DBMR, University of Bern, Bern, Switzerland.
Jessie KohlerExperimental Haemostasis Group, Department for BioMedical Research, DBMR, University of Bern, Bern, Switzerland.
Lorenz JennyExperimental Haemostasis Group, Department for BioMedical Research, DBMR, University of Bern, Bern, Switzerland.
Elaissa T HardyWallace H. Coulter Department of Biomedical Engineering, Georgia Institute of Technology and Emory University, Atlanta, GA, United States.
József DobóInstitute of Enzymology, Research Centre for Natural Sciences, Budapest, Hungary.
Péter GálInstitute of Enzymology, Research Centre for Natural Sciences, Budapest, Hungary.
Gábor PálDepartment of Biochemistry, Eötvös Loránd University, Budapest, Hungary.
Bence KissDepartment of Biochemistry, Eötvös Loránd University, Budapest, Hungary.
Wilbur A LamWallace H. Coulter Department of Biomedical Engineering, Georgia Institute of Technology and Emory University, Atlanta, GA, United States.
Verena SchroederExperimental Haemostasis Group, Department for BioMedical Research, DBMR, University of Bern, Bern, Switzerland.
University of Bern · CHEötvös Loránd University · HUInstitute of Molecular Life Sciences · HUGeorgia Institute of Technology · USThe Wallace H. Coulter Department of Biomedical Engineering · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Complement lectin pathway components, in particular mannan-binding lectin (MBL) and MBL-associated serine proteases (MASPs) have been shown to interact with coagulation factors and contribute to clot formation. Here we investigated the role of MBL and MASP-1 in the haemostatic response following mechanical vessel injury in a human microfluidic bleeding model. Methods: We studied haemostasis in a microvascular bleeding model in the presence of human endothelial cells and human whole blood under flow conditions. We monitored incorporation of proteins into the clot with fluorescently labelled antibodies and studied their effects on clot formation, platelet activation, and bleeding time with specific inhibitors. Platelet activation was also studied by flow cytometry. Results: Upon vessel injury, MBL accumulated at the injury site in a well-defined wall-like structure. MBL showed partial colocalisation with fibrin, and strong colocalisation with von Willebrand factor and (activated) platelets. Flow cytometry ruled out direct binding of MBL to platelets, but confirmed a PAR4- and thrombin-dependent platelet-activating function of MASP-1. Inhibiting MBL during haemostasis reduced platelet activation, while inhibiting MASP-1 reduced platelet activation, fibrin deposition and prolonged bleeding time. Conclusion: We show in a microvascular human bleeding model that MBL and MASP-1 have important roles in the haemostatic response triggered by mechanical vessel injury: MBL recognises the injury site, while MASP-1 increases fibrin formation, platelet activation and shortens bleeding time. While the complement lectin pathway may be harmful in the context of pathological thrombosis, it appears to be beneficial during the physiological coagulation response by supporting the crucial haemostatic system.

Indexed as

HemorrhageHemostaticsMannose-Binding LectinMannose-Binding Protein-Associated Serine ProteasesThrombosisBlood CoagulationComplement System ProteinsEndothelial CellsFibrinHumansComplement System ProteinsFibrinHemostaticsMannose-Binding LectinMannose-Binding Protein-Associated Serine ProteasesMASP1 protein, humanMBL2 protein, humancomplement systemhaemostasismannan-binding lectin (MBL)MBL-associated serine protease-1 (MASP-1)microfluidics

Identifiers

PMID36032172
PMCPMC9412763
OpenAlexW4291165733

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.